← All trials
NCT05201001
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2023
- Primary completion
- Dec 31, 2024
- Completion date
- Jul 31, 2026
- First posted
- Jan 21, 2022
- Last posted
- Sep 7, 2022
- Enrollment
- 90
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nordic Society of Gynaecological Oncology - Clinical Trials UnitLead sponsor
- GSO Global Clinical Research BVCollaborator
- Katholieke Universiteit LeuvenCollaborator
- Nordic Society for Gynaecologic OncologyStudy chair
- Central and Eastern European Oncology GroupCollaborator
- Swiss Go Trial GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.